NeuroSense reports 20% of people with ALS from Phase 2a study remain on PrimeC

In a regulatory filing, NeuroSense (NRSN) Therapeutics stated: “As of August 20, 2025, approximately 20% of people with ALS from the Company’s Phase 2a study – including those continuing under compassionate use – remain on PrimeC for more than 5.5 years, having lived with ALS for over 7 years. Across these multi-year exposures, treatment remains well tolerated, with no new safety signals observed to date.”